Africa may be the only pharmaceutical market where genuinely high growth is still achievable. Here’s what’s driving that strength and how companies should react.
The medical device industry is no stranger to costly recalls with serious impact on a company’s stock price, bottom line, and most importantly their reputation.
In 2010, Baxter was ordered by FDA to recall AND destroy all Colleague volumetric infusion pumps that had been sold in the market.
It’s a demographic sweet spot of enormous potential. With the developed world (Japan, Europe and to a lesser extent, the US) getting older, and emerging markets getting both bigger and richer, the market for things that make consumers healthier is set to expand. And it is already a very big deal (see chart).
The science of genomics is at the beginning of a new era of innovation. The rapidly declining cost of gene sequencing is making huge amounts of genetic data available, and the full power of information technology is being applied to vastly speed up the process of analyzing these data to discover how genes determine traits or mutate to cause disease.